Seed AI companies in London

LYMA is the breakout pioneer of world-leading anti-aging innovations. The LYMA Laser and the LYMA Laser PRO are powered by patented, cold laser technology engineered to deliver transformational cosmetic surgery results painlessly, at home andon the go. LYMA Skincare is the most active, epigenetic skin science in existence. The LYMA Supplement transforms sleep and stressby radically upgrading the body’s systems and increasing cellular health through its powerful anti-inflammatory formula and deliver the baseline for robust, foundational health: pure, preventative longevity science. Nothing as transformative as the LYMA System has ever existed. Until now.

• Seed
• 110 employees
• Founded 2018

Clerkenwell Health is building the UK’s leading specialist neuro and psychiatry site network, created to raise the standard of how CNS clinical trials are run. With three purpose-built research sites - including a first-of-its-kind NHS-partnered facility - and two more planned by 2026, we’re expanding access to high-quality research across the UK.Since 2021, we’ve worked with 20+ biotechs developing treatments for depression, PTSD, anxiety, addiction, pain and cognitive disorders. Our model blends specialist trial design, compassionate patient care and a purpose-built site network to deliver faster, more reliable trial outcomes, helping bring the next generation of neurological and mental health treatments to market.

• Seed
• 60 employees
• Founded 2020

ETA’s core knowledge and patented technologies deliver market-leading product efficiencies through highly cost-efficient solutions for our customers.We deliver electric drive systems that replace mechanical and hydraulic drive systems through advanced magnetics, accelerating the transition to sustainable energy and the removal of hydrocarbon fuel sources.Building on 15 years of research and development, our electric motors, controllers, and inverters are some of the most advanced, efficient, cost-effective systems and solutions for vehicles and equipment.

• Seed
• 40 employees
• Founded 2019

Early's at-home urine test is designed to make screening for the earliest signs of serious disease routine. Built by world-class scientists, engineers and designers and fuelled by the conviction that knowing this was possible and not building it was never really an option.Easy, beautiful, necessary. Because too many people still hear “we caught it too late.”Early. Launching Spring 2027.

• Seed
• 35 employees
• Founded 2022

At DaltonTx, we are redefining how technology powers drug discovery — creating the intelligence engine behind tomorrow’s medicines.Our adaptive, AI-enabled platforms give pharma, biotech, and CROs the intelligence backbone modern R&D cannot move forward without. Purpose-built for small molecules and biologics, our technology integrates seamlessly into scientific workflows, learns from every experiment, and accelerates the path from idea to medicine.Unlike traditional project-based models, DaltonTx provides lasting capability: collaborative systems that combine machine learning, software engineering, and deep drug discovery expertise. The result is technology that learns from every scientist, model, and experiment — guiding better decisions, evolving with your science, and helping you deliver breakthrough therapies to patients faster.Founded by scientists for scientists, DaltonTx brings together decades of real-world experience in drug discovery, software engineering, and AI. The team — Dr Garry Pairaudeau, Adrian Rossall, Dr Anthony Bradley, and Professor Charlotte Deane MBE — has built pioneering AI discovery platforms at AstraZeneca and Exscientia, while also drawing on world-leading academic research from the University of Oxford. This unique combination of industry execution and academic excellence positions DaltonTx at the forefront of AI-enabled drug discovery.

• Seed
• 23 employees
• Founded 2024